Europe Approves Bristol Myers' Cell Therapy Breyanzi For Patients With Certain Type Of Blood Cancer
EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained ...
Bristol-Myers Squibb (NYSE:BMY) Gets EC Nod For Breyanzi In NHL Treatment
Bristol-Myers Squibb (NYSE:BMY) recently gained European Commission approval for Breyanzi, broadening treatment options for ...
Precision Medicine Online12h
BMS's Breyanzi Gains European Approval as Third-Line Treatment for Follicular Lymphoma
The EC approved the CAR T-cell therapy based on data from a Phase II study showing a 94 percent complete response rate.
Investing.com Australia17h
European Commission expands approval for Bristol Myers Squibb’s lymphoma therapy
Investing.com -- The European Commission has granted Bristol Myers (NYSE: BMY) Squibb, the biopharmaceutical company based in ...
Bristol Myers Gets Expanded European Approval for Breyanzi
Bristol Myers Squibb has won European Commission expanded approval of its CAR-T cell therapy Breyanzi in the blood cancer lymphoma.
Le Lézard18h
BEASLEY BROADCAST GROUP TO REPORT 2024 FOURTH QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL AND WEBCAST ON MARCH 20
Beasley Broadcast Group, Inc. ("Beasley" or the "Company"), a multi-platform media company, announced today that it will report its 2024 full-year financial results before the market opens on Thursday ...
Bristol Myers announces EC approval of Breyanzi
Squibb announced that the European Commission has granted approval to Breyanzi, a CD19-directed chimeric antigen receptor T ...
Le Lézard18h
Life Time Launches All-New 60XT Challenge with $200,000 in Grand Prizes on the Line, Including $10K Cash for Top Five Finishers
Life Time  is launching an all-new challenge, 60XT, just in time to transform for summer. The Challenge kicks off March 24, and registration is now open via the Life Time app or in club for the ...